Publications by authors named "Marina Gomez-Rey"
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are.
View Article and Find Full Text PDFArticle Synopsis
- FGFR2 fusions, found in 10-15% of intrahepatic cholangiocarcinoma (iCCA) patients, may benefit from FGFR inhibitors, and this study evaluated detecting these fusions in plasma samples.
- In a study of 18 iCCA patients with known FGFR2 fusions, 88.9% tested positive for the fusion in plasma, suggesting that lower levels of circulating tumor DNA (ctDNA) correlate with better clinical outcomes.
- The research indicates that monitoring plasma biomarkers can not only predict treatment success but also detect disease progression earlier than traditional imaging methods, aiding in better clinical management for iCCA patients.
Article Synopsis
- Breast cancer diagnosed during pregnancy (PrBC) and postpartum (PPBC) tends to be found at more advanced stages, leading to a poorer prognosis, especially with PPBC being very aggressive.
- Researchers discovered that cell-free tumor DNA (ctDNA) can be detected in breast milk (BM) from breast cancer patients, showing higher detection rates compared to plasma samples.
- This study suggests that using BM for ctDNA analysis could serve as a novel liquid biopsy method, allowing for earlier detection of breast cancer, even months before standard diagnosis techniques.
Article Synopsis
- Liquid biopsy, specifically plasma ctDNA analysis, has potential but its effectiveness in capturing detailed tumor characteristics for clinical use is still being explored.
- In a study with 459 metastatic breast cancer patients, machine learning techniques were applied to ctDNA to uncover complex biological features similar to traditional tumor tissue analysis.
- The research identified four DNA subtypes and a specific ctDNA genomic signature linked to poor treatment response and survival outcomes, highlighting the potential for ctDNA to serve as a valuable predictor in cancer treatment.